medicine

Adding a Cinematic Twist to ‘Magic Mushrooms' as Medical Treatment

The hypothesis of new clinical trial is that a nature film can enhance psychedelic-assisted therapy for alcohol addiction and potentially other conditions

NBCUniversal Media, LLC

It will come as a surprise to some that a clinical trial at a major metropolitan hospital is testing a treatment for alcohol use disorder that involves psilocybin, better known as the "magic mushroom."

But to those who have been following the expanding research into psychedelic-assisted therapy--for conditions ranging from addiction to depression and PTSD--what's new is not the psilocybin, but combining it with nature-themed video.

"This is a novel approach," said Daniel Kelly, MD and neurosurgeon who is director of the Pacific Neuroscience Institute, part of Providence St. John's Health Center in Santa Monica, conducting the trial.

"Truly groundbreaking" and "historic" are the words used by filmmaker Louie Schwartzberg, who created the video.

The hypothesis is that appropriate video can enhance or "prime" the psilocybin-induced "mystical experience," which previous research has indicated can be effective for patients who desire to resolve psychological challenges.

There is need for new approaches, given the inconsistent results of traditional addiction treatments.

Though perhaps best remembered in popular culture as a recreational accessory of the 60's counter-culture, recognition of psilocybin's hallucinogenic powers dates back to ancient times.

"There's a long history of shamanistic cultures using these very successfully to manage these issues," said Dr. Kelly.

In the 1950s psychedelics, including psilocybin, became the subject of therapeutic research at Harvard University, among other established institutions.

But the excesses of the '60s put such research "into a deep freeze," as Dr. Kelly recounts the prologue, until just before the turn of the new century.

"There's a renaissance in psychedelic-assisted therapy that's been going on now for perhaps the last 20 years," said Dr. Kelly. "To me, as a neuroscientist, I think this is perhaps the most interesting thing going on in the neurosciences right now--because there's so much potential to help so many people in need."

During typical psychedelic therapy with psilocybin, the patient relaxes in a calm space, receives a dose of the active ingredient, and while monitored by one or two trained "guides," goes into a hallucinogenic state for several hours, a "mystical experience," or more simply, a trip. Prior to the treatment program, patients are screened "extensively" and interviewed for suitability, said Dr. Kelly, and then undergo "integration sessions" with a therapist to better understand their issues with the goal of altering their behavior and outlook..

Beyond the physiological fact that psilocybin triggers serotonin receptors, how it works is still not exactly clear. The prevailing sense is that this enables communication between different areas of the brain that don't normally interact,, bypassing and interrupting normal thought patterns in the "default mode network," temporarily turning it off. Dr. Kelly uses the term "ego dissolution" and said it is key.

"This cross-referencing and cross-talk that occurs during the journey is thought to somehow allow people to come to these insights that they couldn't otherwise get as to why…their behavior is so stuck in this rut," Dr. Kelly said.

But in not every case was a standard dose found to produce an adequate "mystical experience" to bring about change.

A considerable portion of the research in recent years has taken place at Johns Hopkins University Medical Center in Baltimore.

Filmmaker Schwartzberg obtained permission to film some of that therapy for his 2019 film Fantastic Fungi, devoted to exploring the mushroom, its place in the world and its powers.

"I think it shaped my life," Schwartzberg said of his own first experience with psilocybin while in college. "It's like the deepest meditative experience."

He became a believer in the healing power of nature, and documenting it became a specialty of his filmmaking.

During his filming at Johns Hopkins, Schwartzberg recalls, seeing patients wearing eye-shades, it occurred to him that nature visuals can be brought into a clinical setting.

"Nature is a healing modality. So I want to be able to bring that into healthcare," said Schwartzberg.

His work has been used at UC San Diego Health's Jacobs Medical Center, where patients can choose the visual ambiance of their room, and also at the University of Texas BrainHealth Center in Dallas.

His opportunity to test his belief that nature visuals can further psychedelic therapy came after he and Dr. Kelly met at a consciousness forum in Madison, Wisconsin. As it was, the sponsor of that forum, the Usona Institute, is now supplying the pharmaceutical psilocybin for the trial.

Under Dr. Kelly, a co-founder of the Pacific Neurosciences Institute, it launched a program called Treatment & Research in Psychedelics, with the conveniently appropriate acronym, "TRIP," under the direction of addiction specialist Keith Heinzerling, MD. He is also the principal investigator of the new trial, the Institute's first, formally known as the "Visual Healing in Psilocybin-assisted Therapy for Aclohol Use Disorder" study. TRIP is planning later trials related to depression and grief.

"Psilocybin-assisted therapy shows promise for treating alcohol use disorder,
but early studies suggest that patients with alcohol problems may be less likely
to achieve a mystical experience with a standard psilocybin dose," stated Dr. Heinzerling.

The goal of achieving the effect without resorting to a larger dose is where the film Schwartzberg created for the trial comes in, with a visual theme of recurring patterns in nature, emphasized with time lapse, slow motion, and other cinema techniques.

"Bending your human perception, by taking the patient on a journey through time and scale," is how Schwartzberg describes it. "And what that does is it opens you up, just as the psilocybin opens you up."

There will also be a control group that does not get "primed" with the video. In all, 20 patients are being treated in the phase two trial.

"Our hypothesis is that these patients who get the nature-themed video will have a higher likelihood of trying to deal with their drinking and reduce their intake or stop drinking altogether," said Dr. Kelly.

He emphasized that a team of professionals work to create the appropriate "set and setting," for every patient; that this is not something to be taken lightly.

Unlike opiates, tobacco, and often alcohol, psilocybin is not considered addictive. It is a controlled substance, schedule 1, the same schedule where you find heroin. But in 2018, the FDA issued a breakthrough therapy designation to several firms developing psilocybin treatments. Under some interpretations, psilocybin could also be prescribed for terminally ill patients under the Right to Try Act of 2018. Several cities have voted to decriminalize, and a bill introduced last month in California's legislature, SB 519, would recognize its therapeutic potential, and legalize possession, use and sharing, but not sale.

Though they are very different drugs, Schwartzberg envisions psilocybin following the path of cannabis to legalized medicinal use. And he's not alone.

"I think this psychedelic renaissance is transforming behavioral healthcare," Dr. Kelly said. "It's long overdue."

Contact Us